PCSK9 Monoclonal Antibody (AN200249P)
For research use only.
| Verified Samples | Verified Samples in IHC: Rat brain |
| Dilution | IHC-P 1:50-1:200 |
| Isotype | IgG1 |
| Host | Mouse |
| Reactivity | Rat |
| Applications | IHC-P |
| Clonality | Monoclonal |
| Immunogen | Recombinant Rat PCSK9 protein |
| Abbre | PCSK9 |
| Synonyms | PCSK, Proprotein convertase, Subtilisin/kexin-like protease PC, Neural apoptosis-regulated convertase, Proprotein convertase subtilisin/kexin type, LDLCQ, HCHOLA, EC 3.4., EC 3.4.21, FH3, HCHOLA3, LDLCQ1, NARC-1, Neural apoptosis-regulated convertase 1, PC9, Proprotein convertase 9, Pcsk9, PCSK9_RAT, Narc1, Proprotein convertase subtilisin/kexin type 9, Neural apoptosis-regulated convertase 1(NARC-1), Proprotein convertase 9(PC9), Subtilisin/kexin-like protease PC9 |
| Swissprot | |
| Cellular Localization | Secreted |
| Concentration | 1 mg/mL |
| Buffer | 0.2 μm filtered solution in PBS |
| Purification Method | Protein A |
| Clone No. | 11A5 |
| Conjugation | Unconjugated |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
| Shipping | Ice bag |
| background | Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
